TY - JOUR
AU - Bruijn, Ernst
AB - Intravesical drug administration is widely used in the treatment of patients with superficial bladder cancer, and aims to optimise drug delivery in the vicinity of the tumour and reduce systemic availability. The most commonly employed intravesical agents in patients with superficial bladder cancer are mitomycin (mitomycin C), thiotepa, etoglucid (ethoglucid), anthracyclines such as doxorubicin, bacille Calmette-Guérin (BCG) and, more recently, taxol and the new mitomycin derivative KW-2149.
TI - Intravesical Drug Delivery
JO - Clinical Pharmacokinetics
DO - 10.2165/00003088-199937010-00004
DA - 2012-10-14
UR - https://www.deepdyve.com/lp/springer-journals/intravesical-drug-delivery-9oROhGPFBf
SP - 59
EP - 73
VL - 37
IS - 1
DP - DeepDyve
ER -